Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 May 23;385(9982):2118-9.
doi: 10.1016/S0140-6736(15)60722-X. Epub 2015 May 6.

Aligning incentives to fulfil the promise of personalised medicine

Victor J Dzau  1 , Geoffrey S Ginsburg  2 , Karen Van Nuys  3 , David Agus  4 , Dana Goldman  5
Affiliations

Aligning incentives to fulfil the promise of personalised medicine

Victor J Dzau et al. Lancet. .

Erratum in

  • Department of Error.
    [No authors listed] [No authors listed] Lancet. 2015 Jun 27;385(9987):2576. doi: 10.1016/S0140-6736(15)60306-3. Epub 2015 Apr 26. Lancet. 2015. PMID: 26122161 No abstract available.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of interests

The World Economic Forum provided a grant for this work. GSG has acted as a consultant for US Diagnostic Standards, has participated in advisory boards and holds stock options for Omicia and CardioDx, has participated in advisory boards for Interleukin Genetics, Pappas Ventures, Q-CROC/PMPC/PreThera, TheHeart.org, Medscape/WebMD, has received grants from Novartis and Merck, acts as Editor at Large for Genome, is a consultant for Third Point and TGEN Health Ventures, and receives royalties from Elsevier, outside the submitted work. KVN is an employee of and DG is a partner at Precision Health Economics, a company providing consulting services to the life-sciences industry. DA co-founded Navigenics in 2006, but has had no financial interest in the company since February, 2010. VJD declares no competing interests.

Figures

Figure 1:
Figure 1:
Value of Health from Hypothetical PPM Prevention Innovation at Two Levels of Incidence Reduction in Six Diseases in the US ($ billions)
See this image and copyright information in PMC

Comment in

  • The promise of personalised medicine.
    Matuchansky C. Matuchansky C. Lancet. 2015 Aug 22;386(9995):742. doi: 10.1016/S0140-6736(15)61541-0. Lancet. 2015. PMID: 26333977 No abstract available.
  • The promise of personalised medicine.
    Doble B, Schofield DJ, Roscioli T, Mattick JS. Doble B, et al. Lancet. 2016 Jan 30;387(10017):433-4. doi: 10.1016/S0140-6736(16)00176-8. Lancet. 2016. PMID: 26869572 No abstract available.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Feero WG, Guttmacher AE, Collins FS. Genomic Medicine — An Updated Primer. New England Journal of Medicine 2010;362:2001–11. - PubMed
    1. Michaud PC, Goldman D, Lakdawalla D, Gailey A, Zheng Y. Differences in health between Americans and Western Europeans: Effects on longevity and public finance. Social Science & Medicine 2011;73:254–63. - PMC - PubMed
    1. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine 2002;346:393–403. - PMC - PubMed
    1. Goldman D, Gupta C, Vasudeva E, et al. The Value of Diagnostic Testing in Personalized Medicine. Forum for Health Economics & Policy 2013;16:121–33. - PubMed